TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuous Renal Replacement Therapy With Anticoagulation-free Regimen in Bleeding-risk Patients Using oXiris Membrane - CARROM Study
Brief Summary: The investigators hypothesize that the use of heparin-grafted membrane versus conventional membrane in critically-ill patients with bleeding-risk undergoing continuous renal replacement therapy, will effectively prolong the circuit lifespan, without worsening of the systemic APTT or underlying bleeding risk.


Options:
A: Arm Label: oXiris as first filter; Type: ACTIVE_COMPARATOR; Interventions: Device: oXiris as first filter | Arm Label: M150 as first filter; Type: OTHER; Interventions: Device: M150 as first filter | Intervention Type: DEVICE; Name: oXiris as first filter; Assigned to Arm(s): oXiris as first filter | Intervention Type: DEVICE; Name: M150 as first filter; Assigned to Arm(s): M150 as first filter
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous venvenous hemofiltration (CVVH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous venovenous hemodialysis (CVVHD) | Intervention Type: DEVICE; Name: Continuous venvenous hemofiltration (CVVH); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Continuous venovenous hemodialysis (CVVHD); Assigned to Arm(s): 2
C: Arm Label: oXiris™ filter; Type: EXPERIMENTAL; Interventions: Device: oXiris™ filter | Arm Label: Toraymyxin Filter; Type: EXPERIMENTAL; Interventions: Device: Toraymyxin Filter | Arm Label: Standard of Care; Type: OTHER; Interventions: Device: Standard of Care | Intervention Type: DEVICE; Name: oXiris™ filter; Assigned to Arm(s): oXiris™ filter | Intervention Type: DEVICE; Name: Toraymyxin Filter; Assigned to Arm(s): Toraymyxin Filter | Intervention Type: DEVICE; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: Femoral route; Type: EXPERIMENTAL; Interventions: Procedure: Femoral route for hemodialysis | Arm Label: Jugular route; Type: EXPERIMENTAL; Interventions: Procedure: Jugular route for hemodialysis | Intervention Type: PROCEDURE; Name: Femoral route for hemodialysis; Assigned to Arm(s): Femoral route | Intervention Type: PROCEDURE; Name: Jugular route for hemodialysis; Assigned to Arm(s): Jugular route

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label Study to Assess the Safety and Tolerability of a Single Intrathecal Dose of ISIS 396443 in Patients With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1
Brief Summary: The primary objective of this study is to examine the safety and tolerability of nusinersen (ISIS 396443) administered intrathecally to participants with Spinal Muscular Atrophy (SMA) who previously participated in ISIS 396443-CS1 (NCT02865109). The secondary objective was to examine the plasma pharmacokinetics of a single dose of ISIS 396443 administered intrathecally to participants with SMA who previously participated in ISIS 396443-CS1.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Intervention Type: BIOLOGICAL; Name: AVXS-101; Assigned to Arm(s): Cohort 1, Cohort 2
B: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure
C: Intervention Type: DRUG; Name: Valproic Acid; Assigned to Arm(s): N/A
D: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Brief Summary: This randomized phase III trial studies armodafinil to see how well it works in reducing cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve fatigue in patients with high grade glioma.


Options:
A: Arm Label: WBRT with Hippocampal Avoidance; Type: OTHER; Interventions: Radiation: intensity-modulated radiation therapy | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): WBRT with Hippocampal Avoidance
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: armodafinil 150 mg | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Arm III; Type: EXPERIMENTAL; Interventions: Drug: armodafinil 250 mg | Intervention Type: DRUG; Name: armodafinil 150 mg; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: armodafinil 250 mg; Assigned to Arm(s): Arm III
C: Arm Label: ketogenic diet and transient fasting; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calorie-restricted ketogenic diet and transient fasting | Arm Label: standard nutrition; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: calorie-restricted ketogenic diet and transient fasting; Assigned to Arm(s): ketogenic diet and transient fasting | Intervention Type: DIETARY_SUPPLEMENT; Name: standard nutrition; Assigned to Arm(s): standard nutrition
D: Arm Label: WBRT + Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine, Radiation: Whole brain radiation therapy | Arm Label: HA-WBRT/IMRT+ Memantine; Type: EXPERIMENTAL; Interventions: Radiation: Whole brain radiation therapy with hippocampal avoidance, Drug: Memantine | Intervention Type: RADIATION; Name: Whole brain radiation therapy with hippocampal avoidance; Assigned to Arm(s): HA-WBRT/IMRT+ Memantine | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): HA-WBRT/IMRT+ Memantine, WBRT + Memantine | Intervention Type: RADIATION; Name: Whole brain radiation therapy; Assigned to Arm(s): WBRT + Memantine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients
Brief Summary: A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. \& Celebrex Cap. for Comparative Evaluation of Safety \& Efficacy in Rheumatoid Arthritis Patients


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac + Omeprazole | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Diclofenac + Omeprazole; Assigned to Arm(s): B
B: Arm Label: Pelubiprofen 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Pelubiprofen 30 mg | Arm Label: Celebrex 200 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Celebrex 200 mg | Intervention Type: DRUG; Name: Pelubiprofen 30 mg; Assigned to Arm(s): Pelubiprofen 30 mg | Intervention Type: DRUG; Name: Celebrex 200 mg; Assigned to Arm(s): Celebrex 200 mg
C: Arm Label: celecoxib; Type: EXPERIMENTAL; Interventions: Drug: celecoxib | Arm Label: ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Arm Label: naproxen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naproxen | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): celecoxib | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): ibuprofen | Intervention Type: DRUG; Name: Naproxen; Assigned to Arm(s): naproxen
D: Intervention Type: DRUG; Name: celecoxib, esomeprazole; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study on the Clinical Course Of Pulmonary Embolism
Brief Summary: The course of both pulmonary embolism (PE) and one of its more relevant late complications, i.e. chronic thromboembolic pulmonary hypertension (CTEPH) is still substantially unknown.

Recent evidence has shown that the incidence of CTEPH is higher than previously believed, but this has not been confirmed by other studies. A clear link between PE and CTEPH has been questioned by some experts. A great number of patients affected by PE persistently have residual chronic thromboembolic material the meaning of which is a matter of debate. The evidence sustaining a link between chronic residual PE and subsequent PE recurrences or CTEPH is insufficient.

Thus, a nationwide, multicentre, prospective cohort study was designed with the following aims:

1. to ascertain the incidence of symptomatic CTEPH after a first episode of acute PE;
2. to ascertain the incidence of venous thromboembolic (VTE) recurrences after a first episode of acute PE;
3. to evaluate whether a relation exists between chronic residual PE and CTEPH
4. to evaluate whether a relation exists between chronic residual PE and VTE recurrences;
5. to evaluate whether a relation exists between persistent right ventricular dysfunction and CTEPH;
6. to evaluate whether a relation exists between persistent right ventricular dysfunction and PE recurrences.

For each enrolling centre, consecutive outpatients or inpatients with an objectively diagnosed first acute PE episode are considered eligible.


Options:
A: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A
B: Arm Label: pulmonary embolism; Type: N/A; Interventions: N/A
C: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
D: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Drug: tenecteplase (group A) | Arm Label: group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo ( group B) | Intervention Type: DRUG; Name: placebo ( group B); Assigned to Arm(s): group B | Intervention Type: DRUG; Name: tenecteplase (group A); Assigned to Arm(s): group A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).
Brief Summary: This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.


Options:
A: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
B: Arm Label: GSK573719/GW642444 125/25; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 125/25 | Arm Label: GSK573719/GW642444 62.5/25; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 62.5/25 | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: GW642444 | Arm Label: tiotropium bromide; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium bromide | Intervention Type: DRUG; Name: GSK573719/GW642444 125/25; Assigned to Arm(s): GSK573719/GW642444 125/25 | Intervention Type: DRUG; Name: GSK573719/GW642444 62.5/25; Assigned to Arm(s): GSK573719/GW642444 62.5/25 | Intervention Type: DRUG; Name: GW642444; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: tiotropium bromide; Assigned to Arm(s): tiotropium bromide
C: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: QAB149; Type: ACTIVE_COMPARATOR; Interventions: Drug: QAB149 | Arm Label: NVA237; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: QAB149; Assigned to Arm(s): QAB149 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).
Brief Summary: This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.


Options:
A: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 125/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 125mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: GW642444 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo only | Intervention Type: DRUG; Name: GSK573719/GW642444 125/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: GSK573719 125mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GW642444 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo only; Assigned to Arm(s): Placebo
B: Arm Label: Aclidinium Bromide / Formoterol Fumarate; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide / Formoterol Fumarate | Arm Label: Salmeterol / Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone | Intervention Type: DRUG; Name: Aclidinium Bromide / Formoterol Fumarate; Assigned to Arm(s): Aclidinium Bromide / Formoterol Fumarate | Intervention Type: DRUG; Name: Salmeterol / Fluticasone; Assigned to Arm(s): Salmeterol / Fluticasone propionate
C: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Placebo to fluticasone/salmeterol | Arm Label: fluticasone/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone/salmeterol, Drug: Placebo to QVA149 | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Fluticasone/salmeterol; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to QVA149; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to fluticasone/salmeterol; Assigned to Arm(s): QVA149
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).
Brief Summary: This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.


Options:
A: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
B: Arm Label: Indacaterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium
C: Arm Label: fluticasone furoate/umeclidinium bromide/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF), Drug: vilanterol (VI), Drug: umeclidinium bromide (UMEC) | Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF), Drug: vilanterol (VI) | Arm Label: umeclidinium bromide/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol (VI), Drug: umeclidinium bromide (UMEC) | Intervention Type: DRUG; Name: fluticasone furoate (FF); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: vilanterol (VI); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, fluticasone furoate/vilanterol, umeclidinium bromide/vilanterol | Intervention Type: DRUG; Name: umeclidinium bromide (UMEC); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, umeclidinium bromide/vilanterol
D: Arm Label: Relovair; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI) | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Intervention Type: DRUG; Name: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI); Assigned to Arm(s): Relovair | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients Undergoing IVF Treatment.
Brief Summary: Polycystic ovary syndrome (PCOS) is characterized by enlarged ovaries, menstrual irregularity and hyperandrogenism and is the most common cause of oligoovulatory infertility. Insulin resistance with resulting hyperinsulinemia is also common among women with PCOS, along with increased risk for dyslipidemia, hypertension, diabetes and related cardiovascular consequences. Resveratrol is a natural polyphenol with anti-carcinogenic, anti-proliferative and pro-apoptotic properties, that has been shown to decrease proliferation and steroidogenesis in theca cells, emerging as a potential therapeutic agent in PCOS patients. However, little is known about its potential beneficial effect on oocyte quality as well as other reproductive outcomes, such as implantation an pregnancy rates. The present study evaluates effects of resveratrol on selected biochemical parameters and reproductive outcome among patients with PCOS who undergo in vitro fertilization (IVF).


Options:
A: Arm Label: Antioxidant Supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antioxidant Supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Antioxidant Supplement; Assigned to Arm(s): Antioxidant Supplement | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cholecalciferol + calcium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol and calcium | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Cholecalciferol and calcium; Assigned to Arm(s): Cholecalciferol + calcium | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Resveratrol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Resveratrol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo pills | Intervention Type: DIETARY_SUPPLEMENT; Name: Resveratrol; Assigned to Arm(s): Resveratrol | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo pills; Assigned to Arm(s): Control
D: Arm Label: High dose Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Ergocalciferol | Arm Label: Low dose Vitamin D; Type: SHAM_COMPARATOR; Interventions: Dietary Supplement: Ergocalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol; Assigned to Arm(s): High dose Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol; Assigned to Arm(s): Low dose Vitamin D

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients Undergoing IVF Treatment.
Brief Summary: Polycystic ovary syndrome (PCOS) is characterized by enlarged ovaries, menstrual irregularity and hyperandrogenism and is the most common cause of oligoovulatory infertility. Insulin resistance with resulting hyperinsulinemia is also common among women with PCOS, along with increased risk for dyslipidemia, hypertension, diabetes and related cardiovascular consequences. Resveratrol is a natural polyphenol with anti-carcinogenic, anti-proliferative and pro-apoptotic properties, that has been shown to decrease proliferation and steroidogenesis in theca cells, emerging as a potential therapeutic agent in PCOS patients. However, little is known about its potential beneficial effect on oocyte quality as well as other reproductive outcomes, such as implantation an pregnancy rates. The present study evaluates effects of resveratrol on selected biochemical parameters and reproductive outcome among patients with PCOS who undergo in vitro fertilization (IVF).


Options:
A: Arm Label: Resveratrol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Resveratrol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo pills | Intervention Type: DIETARY_SUPPLEMENT; Name: Resveratrol; Assigned to Arm(s): Resveratrol | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo pills; Assigned to Arm(s): Control
B: Arm Label: Experimental Healthy Lifestyle; Type: EXPERIMENTAL; Interventions: Other: Healthy Lifestyle | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Healthy Lifestyle; Assigned to Arm(s): Experimental Healthy Lifestyle
C: Arm Label: Low Glycemic Index Diet Group; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index Diet Group | Arm Label: Conventional Diet Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Diet Group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Glycemic Index Diet Group; Assigned to Arm(s): Low Glycemic Index Diet Group | Intervention Type: OTHER; Name: Conventional Diet Group; Assigned to Arm(s): Conventional Diet Group
D: Arm Label: IVF only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Weight reduction treatment and IVF; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Low calorie diet treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Low calorie diet treatment; Assigned to Arm(s): Weight reduction treatment and IVF

Answer: A